PSTI - プルリステム・セラピュ―ティクス （Pluristem Therapeutics Inc.） プルリステム・セラピュ―ティクスPSTIのチャート
PSTIの企業情報
| symbol | PSTI |
|---|---|
| 会社名 | Pluristem Therapeutics Inc （プルリステム・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 プルリステム・セラピューティクス(Pluristem Therapeutics Inc.)は生物治療薬の会社であり、変性性、虚血性及び自己免疫性重症疾患の治療向けの非個別化(同種異系)細胞治療製品の商業化に従事する。同社は在庫既製のヒト胎盤由来製品のパイプラインを開発している。上記のヒト胎盤は非論争的な非胚性成体間質細胞の供給源である。胎盤由来の接着間質細胞(ASC)は、身体の自然微細構造を模倣する「PluriX」と言う同社の三次元(3-D)バイオリアクターで栽培される。同社は筋肉内投与経路の臨床適応症を中心としている。該当投与経路は末梢動脈疾患(PAD)、重症虚血肢(CLI)、間欠性跛行、神経因性疼痛、創傷治癒及び整形外科傷害を含む異なる適応症に応用できる。 プルリステム・セラピュ―ティクスは、イスラエルのバイオ医薬品企業。複数の虚血性および炎症治療のための同種細胞治療製品開を開発する。特許取得製品は、PLX（胎盤拡張）細胞。この製品は、三次元プロセスを使用する接着間質細胞で心血管、整形外科、肺及び女性健康などの病気に対応する臨床段階にある。本社はハフィア。 Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a |
| 本社所在地 | MATAM Advanced Technology Park Building No.5 Haifa 31905 ISR |
| 代表者氏名 | Yaky Yanay ヤキヤネイ |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +972 74-710-8600 |
| 設立年月日 | 37012 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 180人 |
| url | www.pluristem.com |
| nasdaq_url | https://www.nasdaq.com/symbol/psti |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -31.71300 |
| 終値（lastsale） | 1.22 |
| 時価総額（marketcap） | 138586489.26 |
| 時価総額 | 時価総額（百万ドル） 136.31460 |
| 売上高 | 売上高（百万ドル） 0.05000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 106.41460 |
| 当期純利益 | 当期純利益（百万ドル） -26.12600 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Pluristem Therapeutics Inc. revenues increased from $0K to $50K. Net loss decreased 6% to $26.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects G/L on Invest. HFS Maturity_Trading increase from $513K (expense) to $8.5M (income) Research and development expenses - Bala decrease of 38% to $11.7M (expense). |
PSTIのテクニカル分析
PSTIのニュース
Peripheral Artery Disease Market to Showcase Growth at a Paltry CAGR of 4% During the Study Period (2019-2032) | DelveInsight 2023/03/29 15:30:00 Kwhen Finance
Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact 2022/07/25 13:20:56 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pluristem Therapeutics Changes its Name To Pluri Pluristem Therapeutics Inc (NASDAQ: PSTI ) will be renamed Pluri Inc and start trading on NASDAQ under the ticker PLUR from July 26. The change reflects a broader strategy of leveraging its 3D cell expansion technology to develop cell-based products that can be harnessed for various fields beyond medicine. AstraZeneca''s Enhertu Under FDA Priority Review For HER2-Low Metastatic Breast Cancer The FDA has accepted AstraZeneca Plc (NASDAQ: AZN ) and Daiichi Sankyo''s (OTC: DSNKY ) supplemental application seeking approval for Enhertu (trastuzumab deruxtecan) for unresectable or metastatic HER2-low breast cancer who have received a prior therapy in the metastatic setting. The application has been granted Priority Review. The Prescription Drug User Fee Act date is during Q4 of 2022. Shares are up 1.66% at $66.33 during the premarket session. CHMP Recommends Approving AstraZeneca''s Asthma, Neuromuscular Disorder Treatments The European Medicines Agency''s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca Plc''s (NASDAQ: AZN ) Ultomiris (ravulizumab) for generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
Pluristem Therapeutics renames as Pluri 2022/07/25 09:55:17 Seeking Alpha
Pluristem Therapeutics (PSTI) said it changed its name to Pluri Inc
Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery 2022/07/13 13:49:18 Benzinga
Pluristem Therapeutics Inc (NASDAQ: PSTI ) announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip fracture. The 240-subject study did not meet the primary endpoint, the Short Physical Performance Battery (SPPB) test at week 26. The SPPB is a series of physical performance tests used in … Full story available on Benzinga.com
PSTI stock on watch as Phase 3 trial for muscle injury therapy fails (NASDAQ:PSTI) 2022/07/13 11:08:34 Seeking Alpha
The clinical-stage biotech Pluristem Therapeutics (PSTI) said on Wednesday that its Phase 3 study for PLX-PAD cells as a treatment for muscle injury following hip fracture surgery, did…
Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact 2022/07/25 13:20:56 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pluristem Therapeutics Changes its Name To Pluri Pluristem Therapeutics Inc (NASDAQ: PSTI ) will be renamed Pluri Inc and start trading on NASDAQ under the ticker PLUR from July 26. The change reflects a broader strategy of leveraging its 3D cell expansion technology to develop cell-based products that can be harnessed for various fields beyond medicine. AstraZeneca''s Enhertu Under FDA Priority Review For HER2-Low Metastatic Breast Cancer The FDA has accepted AstraZeneca Plc (NASDAQ: AZN ) and Daiichi Sankyo''s (OTC: DSNKY ) supplemental application seeking approval for Enhertu (trastuzumab deruxtecan) for unresectable or metastatic HER2-low breast cancer who have received a prior therapy in the metastatic setting. The application has been granted Priority Review. The Prescription Drug User Fee Act date is during Q4 of 2022. Shares are up 1.66% at $66.33 during the premarket session. CHMP Recommends Approving AstraZeneca''s Asthma, Neuromuscular Disorder Treatments The European Medicines Agency''s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca Plc''s (NASDAQ: AZN ) Ultomiris (ravulizumab) for generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
Pluristem Therapeutics renames as Pluri 2022/07/25 09:55:17 Seeking Alpha
Pluristem Therapeutics (PSTI) said it changed its name to Pluri Inc
Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery 2022/07/13 13:49:18 Benzinga
Pluristem Therapeutics Inc (NASDAQ: PSTI ) announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip fracture. The 240-subject study did not meet the primary endpoint, the Short Physical Performance Battery (SPPB) test at week 26. The SPPB is a series of physical performance tests used in … Full story available on Benzinga.com
PSTI stock on watch as Phase 3 trial for muscle injury therapy fails (NASDAQ:PSTI) 2022/07/13 11:08:34 Seeking Alpha
The clinical-stage biotech Pluristem Therapeutics (PSTI) said on Wednesday that its Phase 3 study for PLX-PAD cells as a treatment for muscle injury following hip fracture surgery, did…
Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery 2022/07/13 10:00:00 GlobeNewswire
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA
Pluristem''s PLX-R18 Shows Meaningful Advantage Over Other Treatments In Transplant Patients 2022/03/23 16:35:04 Benzinga
Pluristem Therapeutics Inc (NASDAQ: PSTI ) announced final results from its hematology Phase 1 study of intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT). Data collated 12 months post-treatment with PLX-R18 demonstrate that PLX-R18 was well-tolerated with … Full story available on Benzinga.com
Pluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trial 2022/03/23 15:59:38 Seeking Alpha
Pluristem Therapeutics (PSTI) reported final results from a phase 1 trial of intramuscular injections of PLX-R18 in patients with incomplete hematopoietic recovery following…
PSTI, BLRX and BBIG among pre-market gainers 2022/01/18 13:18:34 Seeking Alpha
Mainz Biomed (MYNZ) +14%. Vinco Ventures (BBIG) +13%. Digital World Acquisition (DWACW) +11%. Pluristem Therapeutics (PSTI) +10%
Pluristem Therapeutics Inc Shares Close the Day 10.3% Higher - Daily Wrap 2022/01/16 12:57:46 Kwhen Finance
Pluristem Therapeutics Inc (PSTI) shares closed today 10.3% higher than it did at the end of yesterday. The stock is currently up 32.2% year-to-date, down 76.0% over the past 12 months, and down 87.6% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $2.04 and as low as $1.65 this week.Shares closed 77.6% below its 52-week high and 41.9% above its 52-week low.Trading volume this week was 96.1% lower than the 10-day average and 88.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -525.5% The company's stock price performance over the past 12 months lags the peer average by 130.9%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Thinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals? 2022/01/10 15:55:00 Benzinga
NEW YORK , Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTI, DIDI, HOOD, BITF, and ADMP. Full story available on Benzinga.com